A new approach to measuring estrogen exposure and metabolism in epidemiologic studies.
Endogenous estrogen plays an integral role in the etiology of breast and endometrial cancer, and conceivably ovarian cancer. However, the underlying mechanisms and the importance of patterns of estrogen metabolism and specific estrogen metabolites have not been adequately explored. Long-standing hypotheses, derived from laboratory experiments, have not been tested in epidemiologic research because of the lack of robust, rapid, accurate measurement techniques appropriate for large-scale studies. We have developed a stable isotope dilution liquid chromatography-tandem mass spectrometry (LC-MS(2)) method that can measure concurrently all 15 estrogens and estrogen metabolites (EM) in urine and serum with high sensitivity (level of detection=2.5-3.0fmol EM/mL serum), specificity, accuracy, and precision [laboratory coefficients of variation (CV's) < or =5% for nearly all EM]. The assay requires only extraction, a single chemical derivatization, and less than 0.5mL of serum or urine. By incorporating enzymatic hydrolysis, the assay measures total (glucuronidated+sulfated+unconjugated) EM. If the hydrolysis step is omitted, the assay measures unconjugated EM. Interindividual differences in urinary EM concentrations (pg/mL creatinine), which reflect total EM production, were consistently large, with a range of 10-100-fold for nearly all EM in premenopausal and postmenopausal women and men. Correlational analyses indicated that urinary estrone and estradiol, the most commonly measured EM, do not accurately represent levels of total urinary EM or of the other EM. In serum, all 15 EM were detected as conjugates, but only 5 were detected in unconjugated form. When we compared our assay methods with indirect radioimmunoassays for estrone, estradiol, and estriol and enzyme-linked immunosorbent assays for 2-hydroxyestrone and 16alpha-hydroxyestrone, ranking of individuals agreed well for premenopausal women [Spearman r (r(s))=0.8-0.9], but only moderately for postmenopausal women (r(s)=0.4-0.8). Our absolute readings were consistently lower, especially at the low concentrations characteristic of postmenopausal women, possibly because of improved specificity. We are currently applying our EM measurement techniques in several epidemiologic studies of premenopausal and postmenopausal breast cancer.
Ziegler
R G
RG
Epidemiology and Biostatistics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA. zieglerr@mail.nih.gov
Faupel-Badger
J M
JM
Sue
L Y
LY
Fuhrman
B J
BJ
Falk
R T
RT
Boyd-Morin
J
J
Henderson
M K
MK
Hoover
R N
RN
Veenstra
T D
TD
Keefer
L K
LK
Xu
X
X
D002853:Chromatography, Liquid; D016021:Epidemiologic Studies; D004967:Estrogens / Q000008:administration & dosage* / Q000378:metabolism; D005260:Female; D006801:Humans; D057230:Limit of Detection; D008297:Male; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry
D004967:Estrogens
Curr Drug Metab. 2002 Jun;3(3):321-49
12083324
Mol Cell Endocrinol. 2009 Mar 25;301(1-2):272-81
19007847
Steroids. 2007 Jul;72(8):666-71
17588628
Carcinogenesis. 1998 Jan;19(1):1-27
9472688
Adv Exp Med Biol. 2008;630:148-65
18637490
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):221-6
15668498
J Natl Cancer Inst Monogr. 2000;(27):113-24
10963623
Br J Cancer. 1996 Jun;73(12):1615-9
8664140
Cancer Epidemiol Biomarkers Prev. 1999 Jun;8(6):567-77
10385149
Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3411-8
19064556
Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):292-300
20056650
Anal Chem. 2007 Oct 15;79(20):7813-21
17848096
Biochim Biophys Acta. 2006 Aug;1766(1):63-78
16675129
J Steroid Biochem. 1980 Jan;12:503-8
7421233
Adv Clin Chem. 2004;38:135-49
15521191
J Natl Cancer Inst. 1993 Nov 17;85(22):1819-27
8230262
Br J Cancer. 2003 May 6;88(9):1394-9
12778067
J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):221-36
15860265
Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):81-7
10667467
Endocr Relat Cancer. 2008 Jun;15(2):485-97
18509001
J Steroid Biochem Mol Biol. 2004 Dec;92(5):399-411
15698545
J Natl Cancer Inst. 2002 Apr 17;94(8):606-16
11959894
Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1578-81
16985015
Anal Chem. 2005 Oct 15;77(20):6646-54
16223252
J Endocrinol. 1996 Sep;150 Suppl:S259-65
8943806
Endocrinology. 2003 Aug;144(8):3382-98
12865317
N Engl J Med. 2006 Jan 19;354(3):270-82
16421368
J Natl Cancer Inst. 2005 May 18;97(10):755-65
15900045
J Natl Cancer Inst Monogr. 2000;(27):95-112
10963622
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2860-8
19843676
J Clin Endocrinol Metab. 2006 Oct;91(10):3791-7
16882749
Int J Biol Markers. 2010 Oct-Dec;25(4):185-94
21161939
Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1713-9
17855686